Who Should Not Take Mounjaro — and What the Evidence Actually Says

The myth that most people are ruled out, and why it persists

One of the most common misunderstandings about Mounjaro is that its list of contraindications is so long that most people asking about it won't qualify. That isn't accurate. The absolute contraindications are relatively few and specific. What makes the question complicated is that there is a separate, longer list of situations requiring careful prescriber assessment, not automatic exclusion, but a more detailed conversation. Conflating the two categories leads people either to assume they're automatically unsuitable when they're not, or to underestimate a genuine caution that does need exploring. If you're still forming a view on the basic question, working through whether you should go on Mounjaro can help you frame things before you speak to a prescriber.

The clearest absolute contraindication is a personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2. Animal studies raised a thyroid signal with GLP-1 receptor agonists; in humans the risk remains theoretical, but the precaution is firm. If either applies to you, tirzepatide (and other drugs in this class) is not prescribed. This isn't a grey area a prescriber can work around.

Beyond that, anyone with a known serious hypersensitivity to tirzepatide or any component of the pen is excluded. That's straightforward. Everything else sits in a zone of clinical judgement, not blanket prohibition. If you're unsure where your history places you, reading through the question of whether Mounjaro is right for you in detail is a useful starting point before a consultation.

Conditions where tirzepatide who should not take guidance is firm

Pancreatitis is the condition that generates the most questions. A history of acute or chronic pancreatitis isn't listed as a hard absolute contraindication in the way MTC is, but most prescribers will not start tirzepatide in someone with a confirmed history of the condition without careful consideration, and many will decline. The MHRA Drug Safety Updates index includes a January 2026 update specifically highlighting acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines. Severe stomach pain spreading to the back, with or without vomiting, is a red flag requiring urgent medical attention regardless of cause.

Serious gastrointestinal conditions (including gastroparesis and other conditions affecting gastric emptying) are relevant because tirzepatide itself slows gastric emptying. For most people that contributes to feeling full sooner. For someone whose stomach already empties poorly, it can worsen symptoms significantly. Reviewing the full guidance on who shouldn't take Mounjaro gives a clear picture of which conditions sit in this firmer category and which require individual assessment.

Diabetic retinopathy is worth flagging too. People with type 2 diabetes and existing retinopathy should discuss this with a prescriber before starting, because rapid changes in blood glucose control have historically been associated with short-term retinopathy worsening. This doesn't automatically exclude someone, but it needs to be on the table. A quick scan of your most recent eye-check results before your consultation (easy enough to pull from your GP records online) gives the prescriber useful information straight away.

Life circumstances that exclude or pause treatment

Pregnancy is a clear exclusion. Mounjaro is not recommended during pregnancy, during breastfeeding, or for anyone who is actively trying to conceive. Animal studies showed harm to developing foetuses at doses lower than those used in humans, and there is no adequate human safety data. The practical consequence is that women of childbearing age need reliable contraception throughout treatment.

There is a specific nuance for women using oral contraceptive pills alongside tirzepatide. Because the medicine slows gastric emptying, pill absorption can be reduced, particularly in the early weeks of treatment or after a dose increase. NHS guidance recommends adding a non-oral contraceptive method (condoms, for instance) for the first four weeks of treatment and for four weeks after each dose increase, until absorption has stabilised. Transdermal contraceptive patches or injections sidestep this issue entirely. Anyone on HRT should similarly discuss whether a transdermal option would be more appropriate while on tirzepatide.

Age is also a straightforward boundary. Mounjaro holds a licence for adults only. Under-18s are not prescribed it for weight management, full stop. At the other end of the age range, older adults aren't automatically excluded, but kidney function and other factors may need closer monitoring, something the prescriber factors in during assessment. Understanding whether Mounjaro is suitable for your individual circumstances is a good way to prepare for that conversation.

How a clinical assessment works through the grey areas

Most of the situations people worry about fall into the middle category: not disqualifying outright, but needing a trained eye. Kidney disease, liver disease, heart conditions, and a range of common medicines can all interact with tirzepatide in ways that affect whether and how to prescribe it. These aren't reasons to assume you can't take it, they're reasons why a genuine clinical assessment, not a checkbox form, matters. Part of preparing well is also knowing when you should take Mounjaro, including the timing considerations a prescriber will discuss with you.

At our pharmacy, a GPhC-registered Independent Prescriber reads every consultation personally. Your medical history, current medicines, and the specific reasons you're considering treatment are all weighed. If there's a question about suitability, our prescribers raise it directly rather than approve or decline without explanation. The full picture of how tirzepatide works is worth reading before your consultation so you arrive with a clear sense of the mechanism and what questions to ask.

If you've been weighing up whether treatment makes sense for your situation, you can also explore the broader range of weight-loss treatment options to understand where Mounjaro fits. And if you'd like a prescriber to assess your specific circumstances, check your eligibility through a free consultation, there's no obligation and no fee for the assessment itself.